Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Cell Cycle Proteins
/ antagonists & inhibitors
Cell Line, Tumor
Cell Proliferation
/ drug effects
DNA Damage
Drug Administration Schedule
Female
G2 Phase Cell Cycle Checkpoints
/ drug effects
Heterografts
Humans
Mice, Inbred C57BL
Mice, Nude
Mice, SCID
Mitosis
/ drug effects
Neoplasms
/ drug therapy
Poly(ADP-ribose) Polymerase Inhibitors
/ administration & dosage
Protein Kinase Inhibitors
/ administration & dosage
Protein-Tyrosine Kinases
/ antagonists & inhibitors
Signal Transduction
Time Factors
Tumor Burden
/ drug effects
PARP inhibitor
WEE1 inhibitor
replication stress
sequential therapy
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
10 06 2019
10 06 2019
Historique:
received:
21
05
2018
revised:
27
01
2019
accepted:
03
05
2019
entrez:
12
6
2019
pubmed:
12
6
2019
medline:
24
3
2020
Statut:
ppublish
Résumé
We demonstrate that concurrent administration of poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors is effective in inhibiting tumor growth but poorly tolerated. Concurrent treatment with PARP and WEE1 inhibitors induces replication stress, DNA damage, and abrogates the G
Identifiants
pubmed: 31185210
pii: S1535-6108(19)30224-7
doi: 10.1016/j.ccell.2019.05.001
pmc: PMC6642675
mid: NIHMS1533003
pii:
doi:
Substances chimiques
Cell Cycle Proteins
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Protein Kinase Inhibitors
0
Protein-Tyrosine Kinases
EC 2.7.10.1
WEE1 protein, human
EC 2.7.10.2
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
851-867.e7Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217685
Pays : United States
Organisme : NHGRI NIH HHS
ID : U54 HG008100
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA210950
Pays : United States
Organisme : NCRR NIH HHS
ID : P40 RR017447
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA083639
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA098258
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA217842
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published by Elsevier Inc.
Références
Oncogene. 2004 Apr 12;23(16):2825-37
pubmed: 15077146
Mol Cancer Ther. 2004 Apr;3(4):513-9
pubmed: 15078995
Nature. 2005 Mar 31;434(7033):598-604
pubmed: 15800615
Cancer Res. 2005 Dec 1;65(23):10822-9
pubmed: 16322228
Nature. 2006 Nov 30;444(7119):633-7
pubmed: 17136093
J Clin Oncol. 2008 Aug 1;26(22):3785-90
pubmed: 18591545
PLoS One. 2009;4(4):e5120
pubmed: 19357772
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Mol Cancer Ther. 2009 Nov;8(11):2992-3000
pubmed: 19887545
EMBO Mol Med. 2009 Sep;1(6-7):315-22
pubmed: 20049735
Nat Rev Mol Cell Biol. 2010 Mar;11(3):208-19
pubmed: 20177396
Cancer Cell. 2010 Sep 14;18(3):244-57
pubmed: 20832752
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3406-11
pubmed: 21300883
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Clin Cancer Res. 2011 Jul 1;17(13):4200-7
pubmed: 21562035
Neoplasia. 2011 Nov;13(11):1019-25
pubmed: 22131877
Mol Cell Biol. 2012 Oct;32(20):4226-36
pubmed: 22907750
Exp Cell Res. 2013 Mar 10;319(5):684-96
pubmed: 23228958
Oncogene. 2013 Sep 26;32(39):4593-601
pubmed: 23318447
Nature. 2013 Feb 28;494(7438):492-496
pubmed: 23446422
Pharmacol Ther. 2014 Apr;142(1):1-10
pubmed: 24140082
Cell. 2013 Nov 21;155(5):1088-103
pubmed: 24267891
Mol Cancer Ther. 2014 Jun;13(6):1645-54
pubmed: 24694947
Gynecol Oncol. 2014 Oct;135(1):118-24
pubmed: 25093290
J Cell Sci. 2015 Feb 15;128(4):607-20
pubmed: 25609713
Annu Rev Pathol. 2015;10:425-48
pubmed: 25621662
Nat Rev Drug Discov. 2015 Jun;14(6):405-23
pubmed: 25953507
J Clin Oncol. 2015 Oct 20;33(30):3409-15
pubmed: 25964244
Mol Cell. 2015 Sep 17;59(6):1011-24
pubmed: 26365377
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Front Oncol. 2015 Oct 14;5:222
pubmed: 26528434
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Cancer Cell. 2015 Nov 9;28(5):557-568
pubmed: 26602815
Nat Struct Mol Biol. 2016 Feb;23(2):103-9
pubmed: 26840898
Lancet Oncol. 2016 Jul;17(7):943-955
pubmed: 27269740
J Clin Oncol. 2016 Dec 20;34(36):4371-4380
pubmed: 27601554
Annu Rev Genet. 2016 Nov 23;50:155-173
pubmed: 27617969
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
Clin Cancer Res. 2017 Jun 15;23(12):3097-3108
pubmed: 27993965
J Clin Oncol. 2016 Dec 20;34(36):4354-4361
pubmed: 27998224
Cancer Discov. 2017 Jan;7(1):20-37
pubmed: 28003236
Nat Cell Biol. 2016 Dec 23;19(1):1-9
pubmed: 28008184
Mol Cell. 2017 Jan 19;65(2):336-346
pubmed: 28089683
JCI Insight. 2017 Jan 12;2(1):e89760
pubmed: 28097235
Clin Cancer Res. 2017 Aug 15;23(16):4540-4544
pubmed: 28442503
Sci Transl Med. 2017 May 31;9(392):
pubmed: 28566428
Mol Cancer Ther. 2017 Sep;16(9):2022-2034
pubmed: 28619759
Mol Cell. 2017 Jun 15;66(6):735-749
pubmed: 28622519
Drug Des Devel Ther. 2017 Oct 13;11:3009-3017
pubmed: 29075104
Mol Cancer Res. 2018 Feb;16(2):222-232
pubmed: 29133592
Cancer Cell. 2018 Mar 12;33(3):401-416.e8
pubmed: 29533782
Pharmacol Ther. 2018 Aug;188:155-167
pubmed: 29580942
Cell Rep. 2018 May 15;23(7):2095-2106
pubmed: 29768207
Cancers (Basel). 2018 May 19;10(5):null
pubmed: 29783721
Clin Cancer Res. 2018 Oct 15;24(20):5153-5164
pubmed: 29941481
J Exp Clin Cancer Res. 2018 Jun 28;37(1):129
pubmed: 29954437
Science. 2018 Aug 24;361(6404):806-810
pubmed: 30139873
Clin Cancer Res. 2018 Dec 15;24(24):6594-6610
pubmed: 30181387
Cancer Treat Rev. 2018 Dec;71:1-7
pubmed: 30269007
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104
pubmed: 30356138
J Cell Biol. 1998 Mar 23;140(6):1285-95
pubmed: 9508763